LLY vs. TEAM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at LLY and TEAM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | LLY | TEAM |
|---|---|---|
| Company Name | Eli Lilly and Company | Atlassian Corporation |
| Country | United States | Australia |
| GICS Sector | Health Care | Information Technology |
| GICS Industry | Pharmaceuticals | Software |
| Market Capitalization | 623.33 billion USD | 44.25 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | June 1, 1972 | December 9, 2015 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of LLY and TEAM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LLY | TEAM |
|---|---|---|
| 5-Day Price Return | -1.12% | 1.48% |
| 13-Week Price Return | -2.78% | -19.05% |
| 26-Week Price Return | -19.81% | -44.47% |
| 52-Week Price Return | -27.13% | 8.21% |
| Month-to-Date Return | -6.05% | -12.05% |
| Year-to-Date Return | -9.93% | -30.70% |
| 10-Day Avg. Volume | 5.47M | 2.56M |
| 3-Month Avg. Volume | 4.51M | 2.42M |
| 3-Month Volatility | 40.35% | 42.92% |
| Beta | 0.45 | 0.96 |
Profitability
Return on Equity (TTM)
LLY
88.36%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
TEAM
-20.69%
Software Industry
- Max
- 59.01%
- Q3
- 21.98%
- Median
- 7.15%
- Q1
- -11.12%
- Min
- -51.24%
TEAM has a negative Return on Equity of -20.69%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
LLY
25.91%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
TEAM
-4.92%
Software Industry
- Max
- 48.14%
- Q3
- 18.23%
- Median
- 5.60%
- Q1
- -9.22%
- Min
- -49.36%
TEAM has a negative Net Profit Margin of -4.92%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
LLY
32.37%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TEAM
-2.50%
Software Industry
- Max
- 57.34%
- Q3
- 20.60%
- Median
- 7.84%
- Q1
- -8.72%
- Min
- -51.37%
TEAM has a negative Operating Profit Margin of -2.50%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | LLY | TEAM |
|---|---|---|
| Return on Equity (TTM) | 88.36% | -20.69% |
| Return on Assets (TTM) | 16.02% | -4.59% |
| Net Profit Margin (TTM) | 25.91% | -4.92% |
| Operating Profit Margin (TTM) | 32.37% | -2.50% |
| Gross Profit Margin (TTM) | 82.64% | 82.84% |
Financial Strength
Current Ratio (MRQ)
LLY
1.28
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
TEAM
1.22
Software Industry
- Max
- 3.83
- Q3
- 2.31
- Median
- 1.45
- Q1
- 1.03
- Min
- 0.24
TEAM’s Current Ratio of 1.22 aligns with the median group of the Software industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
LLY
2.18
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
TEAM
0.73
Software Industry
- Max
- 2.14
- Q3
- 0.90
- Median
- 0.29
- Q1
- 0.00
- Min
- 0.00
TEAM’s Debt-to-Equity Ratio of 0.73 is typical for the Software industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
TEAM
-11.02
Software Industry
- Max
- 67.02
- Q3
- 19.86
- Median
- 0.70
- Q1
- -12.50
- Min
- -53.00
TEAM has a negative Interest Coverage Ratio of -11.02. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | LLY | TEAM |
|---|---|---|
| Current Ratio (MRQ) | 1.28 | 1.22 |
| Quick Ratio (MRQ) | 0.53 | 1.17 |
| Debt-to-Equity Ratio (MRQ) | 2.18 | 0.73 |
| Interest Coverage Ratio (TTM) | 20.36 | -11.02 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
LLY
0.77%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
TEAM
0.00%
Software Industry
- Max
- 0.08%
- Q3
- 0.03%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEAM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
LLY
36.46%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TEAM
0.00%
Software Industry
- Max
- 1.32%
- Q3
- 0.53%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEAM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | LLY | TEAM |
|---|---|---|
| Dividend Yield (TTM) | 0.77% | 0.00% |
| Dividend Payout Ratio (TTM) | 36.46% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
LLY
47.48
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
TEAM
--
Software Industry
- Max
- 149.35
- Q3
- 100.21
- Median
- 47.97
- Q1
- 26.77
- Min
- 11.68
P/E Ratio data for TEAM is currently unavailable.
Price-to-Sales Ratio (TTM)
LLY
12.30
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
TEAM
8.38
Software Industry
- Max
- 25.24
- Q3
- 13.52
- Median
- 8.15
- Q1
- 4.87
- Min
- 0.98
TEAM’s P/S Ratio of 8.38 aligns with the market consensus for the Software industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
LLY
40.43
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
TEAM
39.62
Software Industry
- Max
- 30.95
- Q3
- 14.91
- Median
- 7.75
- Q1
- 3.60
- Min
- 0.38
At 39.62, TEAM’s P/B Ratio is at an extreme premium to the Software industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | LLY | TEAM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 47.48 | -- |
| Price-to-Sales Ratio (TTM) | 12.30 | 8.38 |
| Price-to-Book Ratio (MRQ) | 40.43 | 39.62 |
| Price-to-Free Cash Flow Ratio (TTM) | 326.03 | 30.86 |